Lilly, Novo bet on amylin obesity drugs after GLP-1s
Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group | Getty Images The next generation of blockbuster obesity drugs isn’t trying to replace GLP-1 medicines. Instead, drugmakers are developing treatments that can complement existing drugs and push weight loss further, or offer new options for potentially
Lilly, Novo bet on amylin obesity drugs after GLP-1s Read More »








